Pfizer Q2 Earnings Call: Analysts Probe Pipeline, Dividend, and Guidance

Earnings
โดย StockStory·US·Read original
Summary · why it matters

Pfizer reported second-quarter results that beat analyst expectations, with revenue of $15.03 billion versus estimates of $14.4 billion and adjusted EPS of $0.77 versus $0.68. The company slightly lifted its full-year revenue guidance to $61.5 billion at the midpoint from $61 billion and reiterated adjusted EPS guidance of $2.90. During the earnings call, analysts questioned management on topics including the MEVPRO-1 prostate cancer trial, Padcev's growth outlook, mevrometostat's commercial potential, atirmociclib efficacy, and dividend sustainability. CEO Albert Bourla asserted the dividend would be maintained even under stressed scenarios and could grow post patent expirations.

Impact on stocks 1

Biotech & Genomic Medicine▲ · 1 stocks
© 2026 MarketDXNews